Nissay Asset Management Corp Japan Has $12.48 Million Position in IDEXX Laboratories, Inc. $IDXX

Nissay Asset Management Corp Japan raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,713 shares of the company’s stock after acquiring an additional 1,056 shares during the quarter. Nissay Asset Management Corp Japan’s holdings in IDEXX Laboratories were worth $12,483,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Pin Oak Investment Advisors Inc. bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $49,000. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth $210,000. Public Employees Retirement System of Ohio bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth $14,767,000. American Capital Management Inc. bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth $85,341,000. Finally, First Bancorp Inc ME acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $500,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Barclays reduced their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. UBS Group boosted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Citigroup upped their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $747.00.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $554.99 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98. The firm has a fifty day moving average of $559.01 and a 200-day moving average of $573.80. The firm has a market capitalization of $43.72 billion, a price-to-earnings ratio of 39.03, a price-to-earnings-growth ratio of 2.96 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.